Avr.O

AVR.O presents a distressed capital structure with negative total equity of -93,000 USD against total liabilities of 23,250,000 USD and total assets of 22,997,000 USD. The company reports a market capitalization of 344,281,414.68 USD, which stands in stark contrast to its negative book value, resulting in a distorted return on equity of 1024.77%. The debt-to-equity ratio is reported as -0.0, reflecting the negative equity base. Liquidity risk is flagged as unknown due to insufficient balance-sheet inputs for a standard assessment, despite the presence of negative operating cash flow.

Profitability is severely impaired, with net income at -94,144,000 USD and operating income at -93,894,000 USD for the latest period. Revenue is minimal at 1,913,000 USD, indicating that the company is not yet generating significant commercial scale relative to its burn rate. The return on assets is -4.14%, highlighting the inefficiency of asset utilization in generating profit. Without cohort median data for comparison, the absolute magnitude of the losses suggests a pre-revenue or early-stage clinical development phase typical of biotech or medtech startups, rather than a mature operating business.

Segment and geographic revenue data are absent from the available information. Consequently, revenue concentration risks cannot be quantified. The lack of disclosed segments implies that the company may be focused on a single product candidate or technology platform, which is common in early-stage health care companies but increases the binary risk profile of the investment.

Growth trajectory analysis is limited by the absence of historical period data. The current revenue of 1,913,000 USD provides a single data point, insufficient to determine year-over-year growth rates or trend stability. The company appears to be in a phase where capital expenditure of 1,954,000 USD is directed toward development or infrastructure rather than scaling existing sales operations.

Risk factors are dominated by the negative equity position and the inability to assess liquidity risk formally. The dilution risk is assessed as low, with basic and diluted shares outstanding both at 41,579,881, suggesting no immediate options or warrants are currently dilutive. However, the negative cash flow from operations of -77,803,000 USD implies a heavy reliance on external financing, which could lead to future dilution if equity raises are required to sustain operations.

Recent observations include analyst coverage with a mean price target of 14.75 USD and a median of 15.00 USD, implying a significant upside from the current market price of 8.28 USD. The mean recommendation is 2.00 (Buy), driven by four Buy ratings and no Hold or Strong Buy ratings. News events indicate system-level reconciler activities rather than fundamental corporate actions, suggesting a lack of recent public disclosures or material events in the news feed.

Revenue $494.0k, −11,2% YoY; Operating income −10,2% YoY.

• ▍Revenue $494.0k, −11,2% YoY
• ▍Operating income −10,2% YoY
• ▍Net income −5,3% YoY
• ▍Free cash flow −4,0% YoY
• ▍Net margin -4660.7%

Revenue $310.0k, −42,2% YoY; Operating income −31,9% YoY.

• ▍Revenue $310.0k, −42,2% YoY
• ▍Operating income −31,9% YoY
• ▍Net income −50,7% YoY
• ▍Free cash flow −51,3% YoY
• ▍Net margin -9420.0%

Revenue $429.0k, −44,2% YoY; Operating income −1,7% YoY.

• ▍Revenue $429.0k, −44,2% YoY
• ▍Operating income −1,7% YoY
• ▍Net income −1,8% YoY
• ▍Net margin -5185.1%

Revenue $618.0k; Operating income -$20.9M.

• ▍Revenue $618.0k
• ▍Operating income -$20.9M
• ▍Net margin -3371.2%

Revenue $556.0k; Operating income -$21.8M.

• ▍Revenue $556.0k
• ▍Operating income -$21.8M
• ▍Net margin -3932.4%

Revenue $536.1k; Operating income -$22.0M.

• ▍Revenue $536.1k
• ▍Operating income -$22.0M
• ▍Net margin -3614.0%

Revenue $1.9M, −29,2% YoY; Operating income −18,4% YoY.

• ▍Revenue $1.9M, −29,2% YoY
• ▍Operating income −18,4% YoY
• ▍Net income −23,4% YoY
• ▍Free cash flow −23,0% YoY
• ▍Net margin -4921.3%

Revenue $2.7M, −1,2% YoY; Operating income −62,9% YoY.

• ▍Revenue $2.7M, −1,2% YoY
• ▍Operating income −62,9% YoY
• ▍Net income −65,8% YoY
• ▍Free cash flow −60,3% YoY
• ▍Net margin -2822.5%